ASH 2023 | Predicting which patients with SMM will progress to multiple myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, addresses the difficulty in predicting which patients will progress from smoldering multiple myeloma (SMM) to multiple myeloma (MM). She highlights the importance of monitoring biomarkers, including M-spike and serum-free light chain (FLC) ratio, along with genomic and proteomic profiling. This approach aims to pinpoint a distinct signature identifying patients at risk of progression, guiding their inclusion in clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Janssen, Oncopeptides, Amgen, Novartis, GlaxoSmithKline, The Binding Site, Window Therapeutics, Pfizer, Regeneron, Menarini Silicon Biosystems, Sanofi, Huron Consulting, Takeda, Aptitude Health, Bristol-Myers Squibb; Honoraria: AbbVie, 10x Genomics, Janssen, Novartis, GlaxoSmithKline, Pfizer, Regeneron, Menarini Silicon Biosystems, Sanofi, Takeda, Vor Biopharma, Adaptive, Bristol-Myers Squibb; Research Funding: Novartis; Ended employment in the past 24 months: Vor Biopharma; Speakers Bureau: Vor Biopharma; Spouse is Chief Medical Officer and holds equity in the company: Disc Medicine.
